ABSTRACT
INTRODUCTION

48
The AMP-activated protein kinase (AMPK) is a major regulator of cellular energy 49 homeostasis that coordinates metabolic pathways in order to balance nutrient supply with 50 energy demand (14, 15, 27, 34) . AMPK is activated by various physiological and pathological 51 energy stresses that increase intracellular ADP:ATP and AMP:ATP ratio, either by 52 accelerating ATP consumption (e.g. muscle contraction) or by decreasing ATP generation 53 (e.g. hypoxia, ischaemia, mitochondrial poisoning). Once activated, AMPK acts to restore 54 energy homeostasis by promoting ATP-production pathways such as glucose uptake and fatty 55 acid oxidation while simultaneously inhibiting ATP-utilization pathways such as lipid and 56 protein synthesis.
57
AMPK is a heterotrimeric complex containing a catalytic subunit (α) and two 58 regulatory subunits (β, γ). Two isoforms of the α and β subunits exist (α1, α2, β1, β2), 59 whereas there are three isoforms of the γ subunit (γ1, γ2, γ3). Isoform expression varies 60 among cells/tissues and also species (36, 41) , with α1, β1 and γ1 appearing in general to be 61 ubiquitously-expressed isoforms. Some isoforms are known to be expressed in a cell/tissue 62 specific/restricted manner, for example α2 is more predominantly expressed in skeletal 63 muscle (22) and also γ3 exclusively found in skeletal muscle (2, 44) . antagonizes the effects of AMP (12, 25) .
70
AMPK has emerged as a key drug target for metabolic disorders such as insulin 71 resistance, cardiovascular disease and type 2 diabetes (19). This is based on numerous reports Thr172 from dephosphorylation through interacting with the β1 subunit. Sepharose. The assay was performed as previously described (18) using Sakamototide peptide
177
(ALNRTSSDSALHRRR) as substrate.
178
Phosphatase protection assay 179 The assay has been performed as previously described (5) 
189
Differences between groups were considered statistically significant when p<0.05. shifting of band mobility of total AMPKα, was robustly enhanced compared to the respective 206 single AICAR dose ( Fig 1A) . were incubated with a recombinant protein phosphatase (λ-phosphatase) for 15 min in vitro.
226
We observed that the upper band-shift induced by the co-treatment was abolished following 227 the phosphatase treatment ( Fig 1C) . To determine if the co-treatment promoted 228 phosphorylation of sites on AMPKα apart from the Thr172 in the activation T-loop residue,
229
we checked another known phosphorylation site (Ser485 on α1 and Ser491 on α2), which is 230 outside of the kinase domain and is proposed to be regulated by Akt (also known as PKB)
231
(20) and p70S6K (4). AICAR alone stimulated the Ser485/Ser491 phosphorylation in a dose-232 dependent manner, while there was no further increase in phosphorylation of this site with co-233 incubation with A769662 (10 µM) ( Fig 1A) . This suggests that the Ser485/Ser491 site is 234 unlikely to be responsible for the band-shift observed in the total and phospho-Thr172 as phosphorylation of AMPK substrates (Fig 1D) compared to AICAR treatment alone (at 0.5 259 and 1 mM) (Fig 1D & E) . We also observed that the co-treatment (AICAR + A769662) (Fig 2A) . Given that Thr172 and its surrounding residues are 271 conserved between AMPKα1 and AMPKα2 isoform and thus the phospho-specific antibody 272 detects both isoforms, we examined whether the co-treatment selectively activates one 273 isoform or both. Individual AMPKα isoform was immunoprecipitated from the hepatocyte 274 lysates (using isoform-specific antibodies) followed by an in vitro kinase assay. We observed 275 that the co-treatment resulted in an increase in AMPK activity at A769662 doses ranging from 276 1 to 30 µM for AMPKα1-containing complexes and 1 and 10 µM for AMPKα2-containing 277 complexes (Fig 2B) . The co-treatment with higher doses of A769662 (100 µM for AMPKα1 278 and 30, 100 µM for AMPKα2) failed to increase AMPK activity above AICAR treatment 279 alone, most likely due to a toxic effect of the compound on hepatocytes.
280
The synergistic effect of A769662 and AICAR co-treatment is ablated in AMPKβ1- (Fig 3A) . β1-null hepatocytes were treated with an increasing dose of AICAR (0, 288 0.01, 0.03, 0.1, 0.3 and 1 mM) and with a fixed dose of A769662 (10 µM). AMPK 289 phosphorylation was still dose-dependently increased by AICAR treatment alone (Fig 3B) . In 290 contrast, the elevation of AMPK phosphorylation upon co-treatment with A769662 observed 291 in wild-type hepatocytes ( Fig 1A) was ablated in the β1-null hepatocytes (Fig 3B) and 292 therefore the activity of AMPK was not affected by the co-treatment either (Fig 3C) fixed dose of A769662 (0.1 μM) showed an additive protection effect by PP2Cα (Fig 5A) . To 324 more directly demonstrate that the observed additive effect is indeed due to A769662 325 interaction with β1 subunit, we used recombinant AMPK complex containing A769662-326 resistant mutant (β1-S108A). In AMPKα2β1(S108A)γ1 complex, AMP was able to protect 327 against dephosphorylation by PP2Cα, while the effect of A769662 was abolished (Fig 5B) .
328
We examined if the enhanced Thr172 phosphorylation by the co-treatment is due to activation (Fig 3) .
357
It has been shown that co-incubation of the fully-phosphorylated (Thr172 residue by substrate, Salt-inducible kinase-2 (SIK2, also known as QIK) (1, 18) and observed that co-367 treatment had no effect (Fig 5C) . This observation is consistent with our previous finding that
368
LKB1 is a constitutively active kinase (29) and AMPK activity is uniquely regulated among 369 other related kinases by its ability to be controlled through adenine nucleotide (i.e. ADP and 370 AMP) binding to the γ subunit (24, 32). Consequently, we showed that the co-treatment 371 displayed a significant additive effect on protection from dephosphorylation via protein 372 phosphatase in cell-free assay (Fig 5A) . However, currently we are not able to demonstrate Another key observation was that the enhanced AMPK activation by co-treatment 376 resulted in a more profound inhibition of lipogenesis compared to single compound treatment 377 in primary hepatocytes (Fig 4) . It would be interesting to see if the co-treatment strategy also 378 works efficiently in whole animal and elicits more pronounced physiological effects 379 downstream of AMPK, for example, in reversing steatosis/fatty liver caused by high fat diet 380 feeding or leptin/leptin-receptor deficiency (i.e. ob/ob or db/db mice). This co-treatment 381 strategy might be attractive from the pharmaceutical point of view as it would potentially be 382 feasible to reduce concentration of the compounds by promoting sensitivity by dual treatment.
383
However, one caveat is that it only works in cells/tissues expressing AMPKβ1 isoform. It has 384 been reported that β2 isoform is predominantly expressed in skeletal muscle and there is very immunoprecipitated from 30 μg extract using 1 μg anti-AMPKα1 and protein G Sepharose.
578
Immune complexes were assayed for AMPK activity (in duplicate 
